Open AccessProgression-Free Survival in Bevacizumab-Based First-Line Treatment for Patients With Metastatic Colorectal Cancer: Is It a Really Good End Point?
Author(s) -
Francesca Montagnani,
Cristina Migali,
Giammaria Fiorentini
Publication year - 2009
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2009.23.1050
Subject(s) - bevacizumab , medicine , colorectal cancer , oncology , cancer , progression free survival , clinical endpoint , end point , overall survival , chemotherapy , randomized controlled trial , geometry , mathematics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom